Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
CNBC’s Investing Club says pharma stocks Eli Lilly and Johnson & Johnson rose as new prescription data from Leerink (using IQVIA) showed Lilly’s oral GLP-1 Foundayo prescriptions up 14% to about 38,900 for week ending Aug. 7, while Novo Nordisk’s oral Wegovy fell 5% to about 163,000. Leerink also cited J&J’s oral IL-23 inhibitor Icotyde prescription acceleration. Rates and software stocks were mixed.
How this was made
The 30-second read
Why it matters
The newest concrete information is the weekly prescription movement for Lilly’s Foundayo versus Novo Nordisk’s oral Wegovy, and the acceleration in J&J’s Icotyde prescriptions tied to payer coverage expansion.
Market read
For traders, the prescription-trend figures provide a near-term demand read-through for two pharma franchises, but they are not a direct earnings or regulatory catalyst.
What to watch
The article does not quantify absolute market size, persistence beyond one week, pricing/reimbursement changes, or whether competitors respond with formulary or marketing actions.
Background
CNBC’s Investing Club Homestretch discusses mixed market action, then highlights a Leerink note using IQVIA weekly prescription trends for US drug demand.
Ticker impact
Leerink’s weekly prescription data shows Lilly’s oral GLP-1 Foundayo prescriptions up 14% to about 38,900 vs Wegovy’s 5% decline.
Mildly positive bias for LLY shares, with follow-through dependent on whether the trend persists in subsequent weekly reads.
The article provides specific, attributable weekly prescription figures and ties them to Lilly’s prior earnings-call marketing ramp timeline, but it is still secondary demand data rather than a new regulatory or earnings event.
Leerink says Johnson & Johnson’s oral IL-23 inhibitor Icotyde prescriptions are accelerating as payers expand coverage.
Moderately positive bias for JNJ, mainly as a sentiment catalyst rather than a fundamental re-rating on its own.
The article cites specific directional demand acceleration and a payer-coverage driver, but does not provide new trial, approval, or financial guidance updates.
Market effects
Reinforces competitive dynamics in oral obesity and oral immunology, potentially shifting relative sentiment within large-cap pharma.
Primarily US large-cap sentiment; no explicit regional spillover beyond general risk appetite.
US prescription-trend data can influence global pharma positioning, but the article does not cite international regulatory or market events.
Counterpoint
Weekly prescription trends can be noisy and may reflect short-term payer timing rather than durable share gains.
Key entities
- companyEli Lilly
Foundayo oral GLP-1 prescriptions rose 14% week over week to about 38,900, per Leerink/IQVIA.
- companyJohnson & Johnson
Icotyde oral IL-23 inhibitor prescriptions are accelerating as payers expand coverage, per Leerink.
- research_firmLeerink
Analyst firm tracking weekly US prescription trends using IQVIA data.
- data_providerIQVIA
Healthcare data and analytics provider used for the weekly prescription-trend reporting.
